Related references
Note: Only part of the references are listed.Association of SGLT2 Inhibitors With Cardiovascular and Kidney Outcomes in Patients With Type 2 Diabetes A Meta-analysis
Darren K. McGuire et al.
JAMA CARDIOLOGY (2021)
Association of Treatment Effects on Early Change in Urine Protein and Treatment Effects on GFR Slope in IgA Nephropathy: An Individual Participant Meta-analysis
Lesley A. Inker et al.
AMERICAN JOURNAL OF KIDNEY DISEASES (2021)
Change in Albuminuria and GFR as End Points for Clinical Trials in Early Stages of CKD: A Scientific Workshop Sponsored by the National Kidney Foundation in Collaboration With the US Food and Drug Administration and European Medicines Agency
Andrew S. Levey et al.
AMERICAN JOURNAL OF KIDNEY DISEASES (2020)
Klotho regulation by albuminuria is dependent on ATF3 and endoplasmic reticulum stress
Vasiliki Delitsikou et al.
FASEB JOURNAL (2020)
Mediators of the effects of canagliflozin on kidney protection in patients with type 2 diabetes
JingWei Li et al.
KIDNEY INTERNATIONAL (2020)
Comparative proteinuria management of different angiotensin-converting enzyme inhibitors or angiotensin receptor blockers for normotensive patients with CKD: a Bayesian network meta-analysis
Huizhen Ye et al.
PEERJ (2020)
Effects of the SGLT2 inhibitor dapagliflozin on proteinuria in non-diabetic patients with chronic kidney disease (DIAMOND): a randomised, double-blind, crossover trial
David Z I Cherney et al.
Lancet Diabetes & Endocrinology (2020)
The dapagliflozin and prevention of adverse outcomes in chronic kidney disease (DAPA-CKD) trial: baseline characteristics
David C. Wheeler et al.
NEPHROLOGY DIALYSIS TRANSPLANTATION (2020)
Effect of Finerenone on Chronic Kidney Disease Outcomes in Type 2 Diabetes
George L. Bakris et al.
NEW ENGLAND JOURNAL OF MEDICINE (2020)
New Insights Into the Role and Mechanism of Partial Epithelial-Mesenchymal Transition in Kidney Fibrosis
Lili Sheng et al.
FRONTIERS IN PHYSIOLOGY (2020)
Renin-angiotensin system inhibitors in hypertensive adults with non-diabetic CKD with or without proteinuria: a systematic review and meta-analysis of randomized trials
Eikan Mishima et al.
HYPERTENSION RESEARCH (2019)
Atrasentan and renal events in patients with type 2 diabetes and chronic kidney disease (SONAR): a double-blind, randomised, placebo-controlled trial
Hiddo J. L. Heerspink et al.
LANCET (2019)
Extracellular Vesicles from Albumin-Induced Tubular Epithelial Cells Promote the M1 Macrophage Phenotype by Targeting Klotho
Yijie Jia et al.
MOLECULAR THERAPY (2019)
Effects of dapagliflozin on development and progression of kidney disease in patients with type 2 diabetes: an analysis from the DECLARE-TIMI 58 randomised trial
Ofri Mosenzon et al.
LANCET DIABETES & ENDOCRINOLOGY (2019)
Proteinuria Reduction as a Surrogate End Point in Trials of IgA Nephropathy
Aliza Thompson et al.
CLINICAL JOURNAL OF THE AMERICAN SOCIETY OF NEPHROLOGY (2019)
Efficacy and renal outcomes of SGLT2 inhibitors in patients with type 2 diabetes and chronic kidney disease
Michael S. Kelly et al.
POSTGRADUATE MEDICINE (2019)
Change in albuminuria and subsequent risk of end-stage kidney disease: an individual participant-level consortium meta-analysis of observational studies
Josef Coresh et al.
LANCET DIABETES & ENDOCRINOLOGY (2019)
Tubular injury triggers podocyte dysfunction by β-catenin-driven release of MMP-7
Roderick J. Tan et al.
JCI INSIGHT (2019)
Bardoxolone Methyl Improves Kidney Function in Patients with Chronic Kidney Disease Stage 4 and Type 2 Diabetes: Post-Hoc Analyses from Bardoxolone Methyl Evaluation in Patients with Chronic Kidney Disease and Type 2 Diabetes Study
Melanie P. Chin et al.
AMERICAN JOURNAL OF NEPHROLOGY (2018)
What Is the Glomerular Ultrafiltration Barrier?
William H. Fissell et al.
JOURNAL OF THE AMERICAN SOCIETY OF NEPHROLOGY (2018)
Albumin downregulates Klotho in tubular cells
Beatriz Fernandez-Fernandez et al.
NEPHROLOGY DIALYSIS TRANSPLANTATION (2018)
SGLT2 inhibitor dapagliflozin limits podocyte damage in proteinuric nondiabetic nephropathy
Paola Cassis et al.
JCI INSIGHT (2018)
Back to the Future: Glomerular Hyperfiltration and the Diabetic Kidney
Katherine R. Tuttle
DIABETES (2017)
Anti-TGF-β1 Antibody Therapy in Patients with Diabetic Nephropathy
James Voelker et al.
JOURNAL OF THE AMERICAN SOCIETY OF NEPHROLOGY (2017)
Albuminuria changes are associated with subsequent risk of end-stage renal disease and mortality
Juan Jesus Carrero et al.
KIDNEY INTERNATIONAL (2017)
The Canagliflozin and Renal Endpoints in Diabetes with Established Nephropathy Clinical Evaluation (CREDENCE) Study Rationale, Design, and Baseline Characteristics
Meg J. Jardine et al.
AMERICAN JOURNAL OF NEPHROLOGY (2017)
SGLT-2 Inhibition: A Potential New Treatment for Diabetic Kidney Disease?
Robert D. Toto
NEPHRON (2017)
Sodium glucose transporter-2 inhibition has no renoprotective effects on non-diabetic chronic kidney disease
Qiuyue Ma et al.
PHYSIOLOGICAL REPORTS (2017)
Prevention of apoptosis averts glomerular tubular disconnection and podocyte loss in proteinuric kidney disease
Ievgeniia Burlaka et al.
KIDNEY INTERNATIONAL (2016)
Megalin and cubilin in proximal tubule protein reabsorption: from experimental models to human disease
Rikke Nielsen et al.
KIDNEY INTERNATIONAL (2016)
Podocyte-actin dynamics in health and disease
Luca Perico et al.
NATURE REVIEWS NEPHROLOGY (2016)
Empagliflozin and Progression of Kidney Disease in Type 2 Diabetes
Christoph Wanner et al.
NEW ENGLAND JOURNAL OF MEDICINE (2016)
Podocyte Depletion in Thin GBM and Alport Syndrome
Larysa Wickman et al.
PLOS ONE (2016)
Sodium-Glucose Linked Cotransporter-2 Inhibition Does Not Attenuate Disease Progression in the Rat Remnant Kidney Model of Chronic Kidney Disease
Yanling Zhang et al.
PLOS ONE (2016)
Progress and controversies in unraveling the glomerular filtration mechanism
Turgay Saritas et al.
CURRENT OPINION IN NEPHROLOGY AND HYPERTENSION (2015)
Megalin/Cubulin-Lysosome-mediated Albumin Reabsorption Is Involved in the Tubular Cell Activation of NLRP3 Inflammasome and Tubulointerstitial Inflammation
Dan Liu et al.
JOURNAL OF BIOLOGICAL CHEMISTRY (2015)
The cell biology of renal filtration
Rizaldy P. Scott et al.
JOURNAL OF CELL BIOLOGY (2015)
SGLT2 inhibitor empagliflozin reduces renal growth and albuminuria in proportion to hyperglycemia and prevents glomerular hyperfiltration in diabetic Akita mice
Volker Vallon et al.
AMERICAN JOURNAL OF PHYSIOLOGY-RENAL PHYSIOLOGY (2014)
Combined Angiotensin Inhibition for the Treatment of Diabetic Nephropathy
Linda F. Fried et al.
NEW ENGLAND JOURNAL OF MEDICINE (2013)
Cardiorenal End Points in a Trial of Aliskiren for Type 2 Diabetes
Hans-Henrik Parving et al.
NEW ENGLAND JOURNAL OF MEDICINE (2012)
Inherited cobalamin malabsorption. Mutations in three genes reveal functional and ethnic patterns
Stephan M. Tanner et al.
ORPHANET JOURNAL OF RARE DISEASES (2012)
Historical Aspects of Proteinuria
Daniel C. Cattran
ADVANCES IN CHRONIC KIDNEY DISEASE (2011)
Cardiovascular and Renal Outcomes With Telmisartan, Ramipril, or Both in People at High Renal Risk Results From the ONTARGET and TRANSCEND Studies
Sheldon W. Tobe et al.
CIRCULATION (2011)
Pirfenidone for Diabetic Nephropathy
Kumar Sharma et al.
JOURNAL OF THE AMERICAN SOCIETY OF NEPHROLOGY (2011)
Etiopathology of chronic tubular, glomerular and renovascular nephropathies: Clinical implications
Jose M. Lopez-Novoa et al.
JOURNAL OF TRANSLATIONAL MEDICINE (2011)
Avosentan for Overt Diabetic Nephropathy
Johannes F. E. Mann et al.
JOURNAL OF THE AMERICAN SOCIETY OF NEPHROLOGY (2010)
TNF Superfamily: A Growing Saga of Kidney Injury Modulators
Maria D. Sanchez-Nino et al.
MEDIATORS OF INFLAMMATION (2010)
Proteinuria: From Ancient Observation to 19th Century Scientific Study
A. Diamantis et al.
JOURNAL OF UROLOGY (2008)
Telmisartan, ramipril, or both in patients at high risk for vascular events
Salim Yusuf et al.
NEW ENGLAND JOURNAL OF MEDICINE (2008)
Properties of the glomerular barrier and mechanisms of proteinuria
Borje Haraldsson et al.
PHYSIOLOGICAL REVIEWS (2008)
TGF-β in renal injury and disease
Erwin P. Bottinger
SEMINARS IN NEPHROLOGY (2007)
Albuminuria is a target for renoprotective therapy independent from blood pressure in patients with type 2 diabetic nephropathy:: Post hoc analysis from the Reduction of Endpoints in NIDDM with the Angiotensin II Antagonist Losartan (RENAAL) trial
Wouter B. A. Eijkelkamp et al.
JOURNAL OF THE AMERICAN SOCIETY OF NEPHROLOGY (2007)
How does proteinuria cause progressive renal damage?
Mauro Abbate et al.
JOURNAL OF THE AMERICAN SOCIETY OF NEPHROLOGY (2006)
Mechanisms of progression and regression of renal lesions of chronic nephropathies and diabetes
G Remuzzi et al.
JOURNAL OF CLINICAL INVESTIGATION (2006)
Renal glomerular permselectivity and vascular endothelium
M Camici
BIOMEDICINE & PHARMACOTHERAPY (2005)
Degradation of albumin by the renal proximal tubule cells and the subsequent fate of its fragments
KP Gudehithlu et al.
KIDNEY INTERNATIONAL (2004)
Causes and consequences of proteinuria: the kidney filtration barrier and progressive renal failure
K Tryggvason et al.
JOURNAL OF INTERNAL MEDICINE (2003)
Retarding progression of chronic renal disease: The neglected issue of residual proteinuria
P Ruggenenti et al.
KIDNEY INTERNATIONAL (2003)
Protein uptake disturbs collagen homeostasis in proximal tubule-derived cells
V Wohlfarth et al.
KIDNEY INTERNATIONAL (2003)
Renal tubular epithelial cell apoptosis is associated with caspase cleavage of the NHE1 Na+/H+ exchanger
KL Wu et al.
AMERICAN JOURNAL OF PHYSIOLOGY-RENAL PHYSIOLOGY (2003)
Urinary free fatty acids bound to albumin aggravate tubulointerstitial damage
A Kamijo et al.
KIDNEY INTERNATIONAL (2002)
Angiotensin-converting enzyme inhibitors and progression of nondiabetic renal disease - A meta-analysis of patient-level data
TH Jafar et al.
ANNALS OF INTERNAL MEDICINE (2001)
Progression, remission, regression of chronic renal diseases
P Ruggenenti et al.
LANCET (2001)
Megalin and cubilin: synergistic endocytic receptors in renal proximal tubule
EI Christensen et al.
AMERICAN JOURNAL OF PHYSIOLOGY-RENAL PHYSIOLOGY (2001)
Share Paper
